Biaoxin Bio is a protein degradation drug developer, focusing on the development of first-in-class or best-in-class protein degradation drugs in the field of oral anti-tumor and autoimmune diseases. It has established a dual-platform cross-fusion of molecular glue and PROTAC. The drug development platform, the product line includes molecular glue and proteolysis targeting chimera, covering multiple hematological and solid tumor fields. Recently, Biaoxin Bio completed the Pre-A+ round of financing. The investor is Pangu Ventures.
This article is reproduced from: https://www.itjuzi.com/investevent/13569903
This site is for inclusion only, and the copyright belongs to the original author.